Association between four MMP-9 polymorphisms and breast cancer risk: A meta-analysis

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1115-1123

  Zhang, Xiaoli ^a   Jin, Guoyin ^a   Li, Jianfeng ^a   Zhang, Linxi ^a  

^a HEBEI NORTH UNIVERSITY   (China)

Author keywords

Breast diseases; Genetic; Matrix metalloproteinase 9; Meta analysis; Polymorphism

Indexed keywords

GELATINASE B; MMP9 PROTEIN, HUMAN;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; DATA BASE; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; GENETIC MODEL; GENOTYPE; HUMAN; META ANALYSIS; PUBLISHING; SENSITIVITY ANALYSIS; BIOLOGICAL MODEL; BREAST TUMOR; DOMINANT GENE; ENZYMOLOGY; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; RECESSIVE GENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BREAST NEOPLASMS; FEMALE; GENES, DOMINANT; GENES, RECESSIVE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; MATRIX METALLOPROTEINASE 9; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS;

EID: 84928158802     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893890     Document Type: Article

References (39)

1. Curado MP: Breast cancer in the world: incidence and mortality. Salud Publica Mex, 2011; 53(5): 372–84
2. Ferlay J, Soerjomataram I, Dikshit R et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015; 136(5): E359–86
3. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. Cancer J Clin, 2014; 64(1): 9–29
4. Youlden DR, Cramb SM, Dunn NA et al: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol, 2012; 36(3): 237–48
5. Nelson HD, Zakher B, Cantor A et al: Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med, 2012; 156(9): 635–48
6. Ren HT, Wang XJ, Kang HF et al: Associations between C1772T polymorphism in hypoxia-inducible factor-1a gene and breast cancer: a meta-analysis. Med Sci Monit, 2014; 20: 2578–83
7. Zhang X, Pu Z, Ge J et al: Association of CYP2D6* 10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit, 2015; 21: 563–69
8. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med, 2009; 360(8): 790–800
9. Yadav L, Puri N, Rastogi V et al: Matrix metalloproteinases and cancer – roles in threat and therapy. Asian Pac J Cancer Prev, 2014; 15(3): 1085–91
10. Nessler MB, Puchała J, Chrapusta A et al: Levels of plasma matrix metalloproteinases (MMP-2 and MMP-9) in response to INTEGRA® dermal regeneration template implantation. Med Sci Monit, 2014. 20: 91–96
11. Wang X, Yu YY, Lieu S et al: MMP9 regulates the cellular response to inflammation after skeletal injury. Bone, 2013; 52(1): 111–19
12. Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA: MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer, 2014; 14: 609
13. St Jean PL, Zhang XC, Hart BK et al: Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann Hum Genet, 1995; 59(Pt 1): 17–24
14. Malaponte G, Polesel J, Candido S et al: IL-6-174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine, 2013; 62(1): 64–69
15. Li X, Qu L, Zhong Y et al: Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol, 2013; 139(9): 1433–47
16. Hu Z, Huo X, Lu D et al: Functional polymorphisms of matrix metalloproteinase- 9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res, 2005; 11(15): 5433–39
17. Slattery ML, John E, Torres-Mejia G et al: Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One, 2013; 8(5): e63165
18. Grieu F, Li WQ, Iacopetta B: Genetic polymorphisms in the MMP-2 and MMP- 9 genes and breast cancer phenotype. Breast Cancer Res Treat, 2004; 88(3): 197–204
19. Roehe AV, Frazzon AP, Agnes G et al: Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat, 2007; 102(1): 123–24
20. Wang X et al: Association between MMP-2 and MMP-9 polymorphsims and breast cancer risk in Chinese female population. Maternal and Child Health Care of China, 2014; 29(7): 1094–97
21. Lei H, Hemminki K, Altieri A et al: Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat, 2007; 103(1): 61–69
22. Fu F, Wang C, Chen LM et al: The influence of functional polymorphisms in matrix metalloproteinase 9 on survival of breast cancer patients in a Chinese population. DNA Cell Biol, 2013; 32(5): 274–82
23. Chiranjeevi P, Spurthi KM, Rani NS et al: Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer. Tumour Biol, 2014; 35(2): 1351–56
24. Holliday DL, Hughes S, Shaw JA et al: Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res, 2007; 9(5): R67
25. Resler AJ, Malone KE, Johnson LG et al: Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer, 2013; 13: 219
26. Chahil JK, Munretnam K, Samsudin N. et al: Genetic polymorphisms associated with breast cancer in Malaysian cohort. Ind J Clin Biochem, 2014; 1–6
27. Sadeghi M, Motovali Bashi M, Hojati Z: MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. International Journal of Integrative Biology, 2009; 6(1): 33–37
28. Zhou P, Du LF, Lv GQ et al: Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 2011; 127(3): 813–18
29. Przybylowska K, Kluczna A, Zadrozny M et al: Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat, 2006; 95(1): 65–72
30. Balduyck M, Zerimech F, Gouyer V et al: Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis, 2000; 18(2): 171–78
31. Farina AR, Mackay AR: Gelatinase B/MMP-9 in tumour pathogenesis and progression. Cancers, 2014; 6(1): 240–96
32. Jones JL, Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol, 1997; 183(4): 377–79
33. Merdad A, Karim S, Schulten HJ et al: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res, 2014; 34(3): 1355–66
34. Liu D, Guo H, Li Y et al: Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One, 2012; 7(2): e31251
35. Bartsch JE, Staren ED, Appert HE: Matrix metalloproteinase expression in breast cancer. J Surg Res, 2003; 110(2): 383–92
36. Pellikainen JM, Ropponen KM, Kataja VV et al: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res, 2004; 10(22): 7621–28
37. Song J, Su H, Zhou YY, Guo LL: Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev, 2013; 14(3): 1615–21
38. Awakura Y, Ito N, Nakamura E et al: Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett, 2006; 241(1): 59–63
39. Beeghly-Fadiel A, Lu W, Shu XO et al: MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Breast Cancer Res Treat, 2011; 126(2): 507–13